The FOCUS data really should not be a surprise to anyone.
Selling because of the results of FOCUS makes no sense to me because it was a poorly designed study. The trial compares two active arms in heavily pretreated patients in which Kyprolis was used at the standard dose, which no one believes is the optimal dose of the drug. The control arm was a steroid with the option of a Dr. adding cyclophosphamide if he/she wanted to (and almost all did) - Why was there not a third arm that combined steroid/cyclo + Kyprolis? The way this study was designed is the major reason for its failure, not the drug.
EU approval will go forward with the better designed ASPIRE data set.